Test Menu Category: Medical Genetics

Background

Genetic testing provides valuable diagnostic and prognostic information about disease risk factors and carrier status that are often important in patient management decisions.

MPLN offers a complement of three molecular testing options to support all clinically relevant indications for CFTR testing including genotyping and patient stratification for clinical trial enrollment; FDA-cleared and approved for use by the New York State Department of Health (NYSDOH Clinical Laboratory Permit #8046).

The illumina Cystic Fibrosis 139 Variant expanded, pan-ethnic panel will detect most mutations targeted by the CFTR potentiator KALYDECO® (Ivacaftor).


Medical Genetics Tests

Abc-Z Molecular Diagnostic Oncology Tests

Cystic Fibrosis Luminex x-TAG 39 Variant Assay

Cystic Fibrosis MiSeqDx 139-Variant Assay by Next Generation Sequencing

Cystic Fibrosis MiSeqDx Clinical Sequencing Assay by Next Generation Sequencing